Inogen, Inc. (NASDAQ:INGN) Stake Lifted by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its position in Inogen, Inc. (NASDAQ:INGN) by 312.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,625 shares of the medical technology company’s stock after purchasing an additional 132,287 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Inogen were worth $1,694,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Divisadero Street Capital Management LP raised its position in Inogen by 682.3% in the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock worth $19,079,000 after acquiring an additional 2,046,766 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Inogen in the 2nd quarter worth approximately $651,000. Monaco Asset Management SAM acquired a new stake in Inogen during the second quarter valued at approximately $610,000. Finally, Stokes Family Office LLC boosted its holdings in Inogen by 162.1% during the second quarter. Stokes Family Office LLC now owns 113,985 shares of the medical technology company’s stock worth $927,000 after buying an additional 70,500 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.

Inogen Stock Performance

Inogen stock opened at $9.78 on Tuesday. The firm’s 50 day moving average price is $9.62 and its two-hundred day moving average price is $9.62. The firm has a market cap of $232.96 million, a PE ratio of -4.17 and a beta of 1.04. Inogen, Inc. has a twelve month low of $4.93 and a twelve month high of $13.33.

Analysts Set New Price Targets

INGN has been the subject of several research reports. StockNews.com lowered Inogen from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Friday, November 8th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.